Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2-part, 2-period fixed-sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite. Fourteen healthy subjects in each part received a single dose of fruquintinib 5 mg alone in Period 1 and with itraconazole (Part A) or rifampin (Part B) in Period 2 under fasted conditions. Itraconazole or rifampin was administered daily 4 or 7 days before coadministration, respectively; administration of both continued throughout the PK sampling period. PK samples were collected before dosing and over 168 hours after fruquintinib dosing. Coadministration with itraconazole resulted in an increase of fruquintinib systemic exposure, determined by area under the plasma concentration-time curves (AUCs) by approximately 10%. Decreases in M11 AUCs and maximum plasma concentration (C) ranged from 44% to 55% but were not considered clinically meaningful. Rifampin reduced fruquintinib C and AUCs by 12% and 65%, respectively. Rifampin had a marginal effect on M11 AUCs and increased M11 C by 2.3-fold. Data support that concomitant use of fruquintinib with potent CYP3A inducers of rifampin-like potency should be avoided, but no dose adjustment is recommended when coadministered with CYP3A inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314110 | PMC |
| http://dx.doi.org/10.1002/cpdd.1520 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of drug-drug interaction with moderate CYP3A inhibitor.
Drug Metab Dispos
August 2025
Translational Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Princeton, New Jersey.
1β-Hydroxydeoxycholic acid (1β-OH DCA) in plasma has been shown to be a promising biomarker to assess drug-drug interaction (DDI) with a strong CYP3A inducer or a strong CYP3A inhibitor. The changes in total 1β-OH DCA (sum of 1β-OH DCA, 1β-OH glycine deoxycholic acid, and 1β-OH taurine deoxycholic acid equivalents) were more significant than those observed from 4β-hydroxycholesterol, which has been limited to the identification of CYP3A inducers, not CYP3A inhibitors. The significant reduction in total 1β-OH DCA in response to strong CYP3A inhibitors led us to further explore its utility as a biomarker for DDI with moderate CYP3A inhibitors.
View Article and Find Full Text PDFDrug-drug interaction liabilities with BTK inhibitor TL-895.
Cancer Res Commun
August 2025
The Ohio State University, Columbus, OH, United States.
TL-895 is an orally administered protein kinase inhibitor in clinical development for the treatment of B-cell malignancies and various other blood and autoimmune disorders. In early stages of drug development, limited data are available to assess off-target engagement and drug-drug interaction (DDI) liabilities, which may have profound effects on drug safety and efficacy. In this context, we characterized the kinase interaction profile of TL-895 and determined that the agent inhibits BTK and BMX, with more potent inhibition of BMX than BTK in a kinase assay (IC50: 0.
View Article and Find Full Text PDFCYP3A mediates drug-drug interactions between atorvastatin and omeprazole: Evidence from in vitro and in vivo studies.
Biochem Pharmacol
August 2025
Changning Maternity and Infant Health Hospital and School of Life Sciences, Shanghai Key Laboratory of Regulatory Biology, East China Normal University, Shanghai, China; Shanghai Institute of Wildlife Epidemics, East China Normal University, Shanghai, China. Electronic address:
The simultaneous use of statins and proton pump inhibitors is common in clinical practice, but the mechanisms behind their potential drug-drug interactions (DDIs) are still not fully understood. This study investigates the cytochrome P450 3A (CYP3A)-mediated interactions between atorvastatin and omeprazole through in vitro microsomal assays and in vivo pharmacokinetic studies in wild-type (WT) and Cyp3a1/2 knockout (KO) rats. Incubation experiments with rat and human liver microsomes demonstrated that omeprazole inhibited atorvastatin metabolism in a concentration-dependent manner.
View Article and Find Full Text PDFPolychlorinated biphenyls (PCBs) interact with drug metabolism in vivo.
Arch Toxicol
August 2025
Institute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Polychlorinated biphenyls (PCBs) are widespread environmental contaminants that interfere with xenobiotic metabolism, primarily by modulating cytochrome P450 (CYP) enzymes. However, their pharmacokinetic consequences in exposed individuals remain poorly defined. Here, we investigated the impact of PCB exposure on CYP enzyme activity using a combined clinical pharmacokinetic and in vitro mechanistic approach.
View Article and Find Full Text PDFKinetic and mechanistic investigation toward the characterization of tucatinib inhibition of CYP3A4.
Drug Metab Dispos
August 2025
Pfizer Inc., Pharmacokinetics, Dynamics & Metabolism, Bothell, Washington. Electronic address:
A highly selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2, tucatinib, has shown remarkable efficacy and safety for treatment of adult patients with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 positive breast cancer, including those with brain metastases. The purpose of this study was to evaluate in vitro the potential to inhibit cytochrome P450 (P450) isoforms for tucatinib. Preliminary in vitro P450 inhibition survey revealed that tucatinib was a weak inhibitor of CYP1A2, CYP2B6, CYP2C19, and CYP2D6 with IC values >20 μM.
View Article and Find Full Text PDF